|
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. |
|
|
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst) |
|
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Merck; Roche |
Speakers' Bureau - AstraZeneca |
Research Funding - Abbvie; Bristol-Myers Squibb |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol Myer Squibb |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech |
Travel, Accommodations, Expenses - Pierre Fabre; Roche |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER |
|
|
Honoraria - Abbott Laboratories |
Consulting or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Merck Serono |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
Expert Testimony - Abbott Laboratories |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Bms spain; Roche |
Consulting or Advisory Role - BeiGene |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bms Spain; MSD; Roche; Roche |
|
|
Honoraria - McCann Health |
Consulting or Advisory Role - Clinigen Group |
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; Merck; Pfizer; Roche; Takeda |
Research Funding - AstraZeneca; Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Basilea; Genmab; Novartis |
Research Funding - Basilea (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Basilea; Roche/Genentech |
|
|
Consulting or Advisory Role - Eisai (Inst); GenMab (Inst); Roche (Inst) |
Speakers' Bureau - Eisai Europe; Eisai Europe (Inst) |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera |
|
Travel, Accommodations, Expenses - Halozyme |
|
|
Honoraria - Bristol Myers Squibb Foundation; Medison; MSD |
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck; Merck |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |